Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system
AimsThe objective of this study is to compare the adverse events (AEs) associated with pralsetinib and selpercatinib.MethodsTo evaluate the imbalance of AEs linked to pralsetinib and selpercatinib in real-world data, the reporting odds ratio (ROR) was utilized to detect potential signals of AEs. Str...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Frontiers Media S.A.
2024-09-01
|
| Cyfres: | Frontiers in Pharmacology |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1424980/full |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|